Credited outlet

Special Report

6 stories written by The Global Wire newsroom from reporting first published by Special Report. Full credit for the original reporting belongs to them.

Visit Special Report →

Stories credited to Special Report

Health8d agoSource: Special Report

Recce Reports Positive Blinded Efficacy Signals in Phase III Diabetic Foot Trial

Initial blinded data from an advanced trial evaluating RECCE 327 Gel in diabetic foot infections point to encouraging therapeutic activity, according to market reporting.

Technology38d agoSource: Special Report

Australian Encryption Firm Senetas Secures Victorian Export Award Amid Global Quantum Cyber Push

Melbourne-based cybersecurity developer Senetas Corporation has been awarded top honors at the 2026 Governor of Victoria Export Awards for its high-speed, quantum-ready encryption…

Health48d agoSource: Special Report

Emyria Advances Sydney Expansion as Empax Psychedelic Clinic Staffing Reaches Milestone

Australian biotech Emyria has assembled its core medical team of therapists and psychiatrists ahead of the planned September launch of its Sydney Empax clinic for MDMA-assisted the…

Health50d agoSource: Special Report

EBR Systems Secures Quality Certification for California Device Facility

Australian-listed medical technology developer EBR Systems has cleared a key quality management milestone at its California plant as it prepares for commercial device production.

Health56d agoSource: Special Report

Prescient Therapeutics Hits Patient Recruitment Benchmark for PTX-100 Lymphoma Trial

The Australian biotech firm has reached the enrollment threshold required to trigger a formal dose optimization review in its Phase 2a study evaluating PTX-100 for T-cell lymphoma.

Health58d agoSource: Special Report

Island Pharmaceuticals Valuation Reaches $1.60 in RaaS Research Report

An equity research assessment from RaaS Research Group values Australian drug developer Island Pharmaceuticals at $1.60 per share, indicating significant upside potential for the A…